Asset Manager

Updated:

Avego Bioscience Capital

Avego Bioscience Capital is a venture capital firm. It has invested $416 million across three deals.

Avego Bioscience Capital

Avego Bioscience Capital is a venture capital firm. It has invested $416 million across three deals. Its focus areas include biotechnology and manufacturing.

General information

Firm type

Asset Manager

Year founded

AUM

Undisclosed

Location

Region

Europe

Country

United Kingdom

City

London

Corporate office

London, United Kingdom

Additional offices

Boston · New York · Dallas · White Plains · Philadelphia · Los Angeles · San Francisco · Chicago

Sector focus

Healthcare ServicesDigital HealthAI/ML

Frequently asked questions

What stage does Avego Bioscience Capital typically invest at?

Avego focuses on early-stage bioscience companies, with an emphasis on seed and Series A rounds. Its office network in research-dense cities suggests a model that engages with academic spinouts and pre-clinical therapeutics developers.

Where does Avego Bioscience Capital maintain offices?

The firm lists offices in London, Boston, New York, Dallas, White Plains, Philadelphia, Los Angeles, San Francisco, and Chicago, per its public registrations. This transatlantic footprint is unusually broad for a specialist bioscience investor.

Does Avego Bioscience Capital invest in therapeutics or digital health?

The firm's mandate covers both therapeutics and digital health, operating at the intersection of biology and computation. Its presence in San Francisco supports exposure to computational biology and AI-driven drug discovery startups, while its East Coast and Texas offices connect it to traditional biotech and clinical research hubs.

Who runs investment decisions at Avego Bioscience Capital?

The firm has not publicly disclosed its investment committee or managing partners. Its distributed office structure may indicate either a network of venture partners or a lean central team supported by regional scientific advisors.

How does Avego Bioscience Capital source its deals?

Deal flow likely originates through relationships with academic technology transfer offices, PI-led research labs, and syndicate partners in Boston and the UK. The firm's London headquarters and US office network provide coverage of both the Golden Triangle and the major US biotech corridors.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More London Asset Manager profiles